Skip to main content
Top
Published in: Netherlands Heart Journal 1/2012

Open Access 01-01-2012 | Editorial

Genetics and tailored therapy in cardiovascular disease

Authors: P. A. Doevendans, F. W. Asselbergs

Published in: Netherlands Heart Journal | Issue 1/2012

Login to get access

Excerpt

Can we today apply genetics to individual patients and tailor therapy based on genetic profile to improve pharmacodynamics and kinetics [1]? This is an interesting question especially for the treatment of hypertension as substantial heterogeneity in efficacy exists in response to drug therapy. Individualised medicine may guide physicians in their choice instead of the old-fashioned trial-and-error strategy to find the perfect cocktail of antihypertensive drugs. In addition, tailored therapy may lead to fewer adverse drug reactions and eventually to a lower burden on health care costs [2]. Although the department of cardiology of the University Medical Center Utrecht is committed to the integration of genetics into clinical medicine, we do not determine a genetic profile in patients on a routine basis [3]. Especially not before prescribing a drug in the clinic or in the outpatient department. But maybe it is time to change our attitude and integrate genetics into daily clinical practice. Nowadays it is technically feasible to determine several single nucleotide polymorphisms (SNPs) within 1 hour at relatively low costs in the outpatient office without the need for specialised laboratory facilities [4, 5]. …
Literature
1.
go back to reference Doevendans PA. Unravelling the pathophysiology of heart failure through human genomics. Eur J Clin Invest. 2001;31:378–9.PubMedCrossRef Doevendans PA. Unravelling the pathophysiology of heart failure through human genomics. Eur J Clin Invest. 2001;31:378–9.PubMedCrossRef
2.
go back to reference Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–59.PubMedCrossRef Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–59.PubMedCrossRef
3.
go back to reference Baars H, van der Smagt J, Doevendans P. Clinical cardiogenetics. London: Springer; 2011.CrossRef Baars H, van der Smagt J, Doevendans P. Clinical cardiogenetics. London: Springer; 2011.CrossRef
4.
go back to reference Harmsze AM, van Werkum JW, Ten Berg JM, et al. Cyp2c19*2 and cyp2c9*3 alleles are associated with stent thrombosis: A case–control study. Eur Heart J. 2010;31:3046–53.PubMedCrossRef Harmsze AM, van Werkum JW, Ten Berg JM, et al. Cyp2c19*2 and cyp2c9*3 alleles are associated with stent thrombosis: A case–control study. Eur Heart J. 2010;31:3046–53.PubMedCrossRef
5.
go back to reference Schimmenti LA, Warman B, Schleiss MR, et al. Evaluation of newborn screening bloodspot-based genetic testing as second tier screen for bedside newborn hearing screening. Genet Med. 2011. Schimmenti LA, Warman B, Schleiss MR, et al. Evaluation of newborn screening bloodspot-based genetic testing as second tier screen for bedside newborn hearing screening. Genet Med. 2011.
6.
go back to reference Brugts JJ, de Maat MPM, Danser AHJ, Boersma E, Simoons ML. Individualised therapy of ACE inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association study. Neth Heart J. 2012;20:xx-xx. Brugts JJ, de Maat MPM, Danser AHJ, Boersma E, Simoons ML. Individualised therapy of ACE inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association study. Neth Heart J. 2012;20:xx-xx.
7.
go back to reference Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the Europa study). Lancet. 2003;362:782–8.PubMedCrossRef Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the Europa study). Lancet. 2003;362:782–8.PubMedCrossRef
8.
go back to reference Brugts JJ, de Maat MP, Boersma E, et al. The rationale and design of the perindopril genetic association study (pergene): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2009;23:171–81.PubMedCrossRef Brugts JJ, de Maat MP, Boersma E, et al. The rationale and design of the perindopril genetic association study (pergene): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2009;23:171–81.PubMedCrossRef
9.
go back to reference Bentley JP, Asselbergs FW, Coffey CS, et al. Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems. PLoS One. 2010;5:e12757.PubMedCrossRef Bentley JP, Asselbergs FW, Coffey CS, et al. Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems. PLoS One. 2010;5:e12757.PubMedCrossRef
10.
go back to reference Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA. 1998;280:605–13. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA. 1998;280:605–13.
Metadata
Title
Genetics and tailored therapy in cardiovascular disease
Authors
P. A. Doevendans
F. W. Asselbergs
Publication date
01-01-2012
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 1/2012
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-011-0231-0

Other articles of this Issue 1/2012

Netherlands Heart Journal 1/2012 Go to the issue